Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787731 | 1.00 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL5788416 | 0.87 | FLT3 (0.33) | PTGS1PTGS2 | |
| SCHEMBL5788412 | 0.87 | FLT3 (0.33) | PTGS1PTGS2 | |
| SCHEMBL5788267 | 0.82 | PTGS1 (0.52) | PTGS1PTGS2 | |
| SCHEMBL5788258 | 0.82 | PTGS1 (0.52) | PTGS1PTGS2 | |
| SCHEMBL5790545 | 0.78 | NFE2L2 (0.51) | — | |
| SCHEMBL5790543 | 0.78 | NFE2L2 (0.51) | — | |
| SCHEMBL5788228 | 0.77 | NPC1 (0.47) | — | |
| SCHEMBL5788233 | 0.77 | NPC1 (0.47) | — | |
| SCHEMBL5791786 | 0.71 | NFE2L2 (0.53) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335906-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| CN-1473156-A | Pyrimidine derivatives and their use as neuropeptide y receptor ligands | - | 2004-02-04 | — | — | CN | disclosed |
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1335906-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | disclosed |
| WO-2002038551-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086858-A1 | Pyrimidine derivatives | NPY1R, NPY5R, NPY4R | PTGS1 2772/4885PTGS2 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.